Eton Pharmaceuticals, Inc.

ETON

US29772L1089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.43 ^USD	-0.15%		-7.55%	-21.69%

May. 09	Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Eton Pharmaceuticals Appoints Paul V. Maier to its Board of Directors

September 14, 2017 at 02:40 pm EDT

Eton Pharmaceuticals, Inc. announced it has appointed Paul V. Maier to its Board of Directors. Paul V. Maier currently serves as a financial advisor to the life science industry. Maier is the former CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc.

Latest news about Eton Pharmaceuticals, Inc.

Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, vs. Street Est of $8M	May. 09	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Apr. 30	MT
Eton Pharmaceuticals Submits New Drug Application to FDA For ET-400	Apr. 30	MT
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)	Apr. 30	CI
Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	Apr. 16	CI
Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	Apr. 14	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Sector Update: Health Care	Mar. 22	MT
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	Mar. 22	CI
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	Mar. 22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	Mar. 22	MT
Transcript : Eton Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q4 Revenue $7.3M, vs. Street Est of $7.66M	Mar. 14	MT
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	Feb. 21	MT
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	Feb. 21	CI
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US	Feb. 02	MT
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules	Feb. 02	CI
Transcript : Eton Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q3 Revenue $7M, vs. Street Est of $6.3M	Nov. 09	MT
Eton Pharmaceuticals to Acquire Nitisinone Drug From Oakrum Pharma	23-10-04	MT
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone	23-10-04	CI

Chart Eton Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Eton Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.43 USD

Average target price

8 USD

Spread / Average Target

+133.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ETON PHARMACEUTICALS, INC.	-21.69%	88.11M
MERCK KGAA	+7.91%	72.81B
KYOWA KIRIN CO. LTD.	+12.64%	9.13B
SK BIOPHARMACEUTICALS CO., LTD.	-10.56%	5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.79%	4.99B
YUHAN CORPORATION	+4.07%	3.9B
BETTA PHARMACEUTICALS CO., LTD.	-16.90%	2.48B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.13%	2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.31%	2.17B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Pharmaceuticals

Eton Pharmaceuticals Appoints Paul V. Maier to its Board of Directors

EPS Revisions